Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Aptamer Group Plc ( (GB:APTA) ) is now available.
Aptamer Group reported interim revenue of £0.83 million for the six months to 31 December 2025, a 27% rise year on year, while narrowing its adjusted EBITDA loss to £1.0 million and ending the period with £1.5 million in cash, supported by a £1.8 million fundraise in July 2025. The group has since launched an Accelerated Book Build expected to raise at least £3.75 million, extending its cash runway to 2028 and funding further asset development and AI-enhanced services.
Operationally, Aptamer advanced its strategic programmes, out-licensing enzyme-modulating Optimers to Twist Bioscience and Alphazyme, expanding manufacturing capacity, and progressing a fibrotic liver delivery vehicle that showed favourable preclinical safety characteristics. It also deepened relationships with global pharma and industrial partners through new and repeat fee-for-service contracts, including a first major radioligand therapy deal and expanding work with Unilever, positioning the company to generate growing product-linked and royalty revenues from its Optimer platform.
The most recent analyst rating on (GB:APTA) stock is a Sell with a £0.62 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.
Spark’s Take on APTA Stock
According to Spark, TipRanks’ AI Analyst, APTA is a Underperform.
The score is primarily held down by very weak financial performance (sharp revenue collapse, continued losses, and negative cash flows). Technical indicators also remain bearish with the stock below major moving averages and negative MACD; oversold momentum readings provide only limited support. Valuation is constrained by a negative P/E and no dividend data.
To see Spark’s full report on APTA stock, click here.
More about Aptamer Group Plc
Aptamer Group plc, listed on AIM, develops next-generation synthetic binders known as Optimers for the life sciences sector, targeting applications in diagnostics, therapeutics and research tools. The company focuses on fee-for-service discovery projects, asset development and licensing partnerships with major pharmaceutical, diagnostic and consumer goods companies.
Average Trading Volume: 4,673,444
Technical Sentiment Signal: Sell
Current Market Cap: £18.88M
For an in-depth examination of APTA stock, go to TipRanks’ Overview page.